4.21 USD
-0.50
10.62%
Updated Dec 30, 12:14 PM EST
1 day
-10.62%
5 days
-18.88%
1 month
0.48%
3 months
36.25%
6 months
132.60%
Year to date
113.71%
1 year
113.71%
5 years
-83.80%
10 years
-77.34%
 

About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Employees: 179

0
Funds holding %
of 6,812 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,300% more call options, than puts

Call options by funds: $14K | Put options by funds: $1K

59% more capital invested

Capital invested by funds: $12.4M [Q2] → $19.8M (+$7.33M) [Q3]

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

3% more funds holding

Funds holding: 33 [Q2] → 34 (+1) [Q3]

2.53% less ownership

Funds ownership: 39.31% [Q2] → 36.77% (-2.53%) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

Research analyst outlook

We haven’t received any recent analyst ratings for XGN.

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
Neutral
GlobeNewsWire
1 month ago
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Neutral
Seeking Alpha
1 month ago
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
Exagen, Inc. (NASDAQ:XGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Participants Mark Massaro – BTIG Daniel Brennan - TD Cowen Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to the Exagen Inc. Third Quarter 2024 Earnings Call.
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.31 per share a year ago.
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
Neutral
GlobeNewsWire
3 months ago
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthcare Conference, which takes place September 17-19, 2024, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen's President and Chief Executive Officer and Jeff Black, Exagen's Chief Financial Officer, will participate in a fireside chat on Wednesday, September 18th, at 9:45 AM ET.
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
Negative
Zacks Investment Research
4 months ago
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
Positive
Zacks Investment Research
4 months ago
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock
Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock
Positive
Zacks Investment Research
4 months ago
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?
Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?
Positive
Zacks Investment Research
4 months ago
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain
Charts implemented using Lightweight Charts™